Tofajak 5mg Tablet

Tofajak 5mg Tablet contains tofacitinib, an oral Janus kinase (JAK) inhibitor used in the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is prescribed for adults who have had an inadequate response to conventional therapies.

Tofacitinib helps reduce inflammation, slow disease progression, and improve joint function and quality of life in patients with autoimmune conditions. Its oral formulation allows convenient administration under medical supervision.

Tofajak 5mg Tablet is intended strictly for use under the guidance of a qualified healthcare professional. This product ensures consistent potency and quality, making it suitable for clinical and pharmaceutical applications where reliable management of inflammatory autoimmune disorders is required.

Product Features

• Contains Tofacitinib 5 mg
• Oral JAK inhibitor for immune-mediated diseases
• Used in rheumatoid arthritis, psoriatic arthritis & ulcerative colitis
• Helps reduce inflammation and disease activity
• Convenient oral tablet formulation
• Suitable for rheumatology & gastroenterology use
• Available for retail, bulk & export supply

How It Helps

• Blocks JAK enzymes to modulate immune system activity
• Reduces inflammation and swelling in joints and tissues
• Helps slow disease progression in autoimmune conditions
• Supports improved mobility and quality of life under medical supervision